# PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) — management_change/board [pending]
Source: SEC API (secapi.ai) · situation sit_b95ff921d7daa749c1a6 · retrieved 2026-08-12T07:21:39.614Z

## Overview
Pacific Biosciences of California, Inc. develops and commercializes long-read DNA sequencing systems, including the Revio and Vega instruments, and provides consumables and related services for genomic analysis.

On July 30, 2026, Pacific Biosciences' Board approved a restructuring plan to align organizational structure with strategic initiatives. The plan includes a reduction in force of approximately 40 employees (approximately 8% of the workforce) and related non-headcount cost actions. The Company expects to reduce annualized operating expenses by $30 million to $40 million by the end of 2027. The Company estimates aggregate pre-tax charges of approximately $2.0 million in connection with the reduction in force, primarily consisting of severance payments, employee benefits, outplacement services and related costs. The reduction in force is expected to be completed in the third quarter of 2026.

## Terms
- Deal value: $2.0M

## Key dates
- Announced 2026-08-05

## Timeline
- 2026-08-05 · 8-K (0001299130-26-000117): 8-K - PACIFIC BIOSCIENCES OF CALIFORNIA, INC. — *Pacific Biosciences of California, Inc. develops and commercializes long-read DNA sequencing systems, including the Revio and Vega instruments, and provides consumables and related services for genomic analysis.* On July 30, 2026, Pacific Biosciences' Board approved a restructuring plan to align organizational structure with strategic initiatives. The plan includes a reduction in force of approximately 40 employees (approximately 8% of the workforce) and related non-headcount cost actions. The Company expects to reduce annualized operating expenses by $30 million to $40 million by the end of 2027. The Company estimates aggregate pre-tax charges of approximately $2.0 million in connection with the reduction in force, primarily consisting of severance payments, employee benefits, outplacement services and related costs. The reduction in force is expected to be completed in the third quarter of 2026.
  https://www.sec.gov/Archives/edgar/data/1299130/0001299130-26-000117.txt

## Citations
- 0001299130-26-000117 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000129913026000117